Pharmacoeconomic Analysis of Micafungin (Mycamine) 100 mg and 150 mg Daily In the Treatment of Candidemia. P & T : a peer-reviewed journal for formulary management [P T] Journal article

We conducted a retrospective study to assess pharmacoeconomic outcomes of patients who received a daily dose of micafungin 100 mg or 150 mg to treat candidemia. The once-daily 100-mg dose resulted in clinical and mycological outcomes similar to those achieved with 150 mg daily and succeeded in reducing drug-acquisition costs for treating hospitalized patients with candidemia.

P & T : a peer-reviewed journal for formulary management [P T]